Matches in UGent Biblio for { <https://biblio.ugent.be/publication/806546#aggregation> ?p ?o. }
Showing items 1 to 35 of
35
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B376984.
- aggregation creator B376985.
- aggregation creator B376986.
- aggregation creator person.
- aggregation date "2009".
- aggregation format "application/pdf".
- aggregation hasFormat 806546.bibtex.
- aggregation hasFormat 806546.csv.
- aggregation hasFormat 806546.dc.
- aggregation hasFormat 806546.didl.
- aggregation hasFormat 806546.doc.
- aggregation hasFormat 806546.json.
- aggregation hasFormat 806546.mets.
- aggregation hasFormat 806546.mods.
- aggregation hasFormat 806546.rdf.
- aggregation hasFormat 806546.ris.
- aggregation hasFormat 806546.txt.
- aggregation hasFormat 806546.xls.
- aggregation hasFormat 806546.yaml.
- aggregation isPartOf urn:issn:1368-5031.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "A comparison of budesonide/formoterol maintenance and reliever therapy vs conventional best practice in asthma management".
- aggregation abstract "Objective: To study the effectiveness and safety of budesonide/formoterol (Symbicort<SU (R)</SU) Maintenance And Reliever Therapy (Symbicort SMART<SU (R)</SU, AstraZeneca, Sodertalje, Sweden), a simplified management approach with one inhaler compared with conventional best practice (CBP) with multiple inhalers in patients with persistent asthma. Design: Open-label randomised controlled parallel group trial, 6-month treatment. Participants: A total of 908 patients >= 12 years of age, with persistent asthma receiving treatment with inhaled corticosteroids (ICS), either alone or in conjunction with long-acting beta(2)-agonist. Main outcome measures: Time to first severe asthma exacerbation and number of severe asthma exacerbations. Results: No difference between groups was seen in time to first severe exacerbation (p = 0.75). Exacerbation rates were low in both groups. A total of 12 patients in the Symbicort SMART<SU (R)</SU group experienced a total of 14 severe asthma exacerbations, and 19 patients in the CBP group experienced a total of 25 severe asthma exacerbations (annual rate 0.07 vs. 0.13 p = 0.09). The mean daily dose of ICS expressed in BDP equivalent was significantly lower in the Symbicort SMART<SU (R)</SU group (including as-needed use) vs. in the CBP group (749 mu g vs. 1059 mu g; p < 0.0001). Mean scores in Asthma Control Questionnaire, 5 question version improved significantly in the SMART group compared with the CBP group (p = 0.0026). Symbicort SMART and CBP were equally well tolerated. The mean drug cost/patient/month was significantly lower for the patients in the Symbicort SMART group compared with patients receiving CBP (51.3 euro vs. 66.5 euro; p < 0.0001). Conclusions: In Belgian patients, a simplified regimen using budesonide/formoterol maintenance and reliever therapy was at least as effective at improving clinical control compared with CBP with a significantly lower ICS dose and significantly lower drug costs.".
- aggregation authorList BK680884.
- aggregation endPage "1488".
- aggregation issue "10".
- aggregation startPage "1479".
- aggregation volume "63".
- aggregation aggregates 811793.
- aggregation isDescribedBy 806546.
- aggregation similarTo j.1742-1241.2009.02185.x.
- aggregation similarTo LU-806546.